Wiegand RA - Search Results

1

Preclinical anticancer activity of cryptophycin-8.

Corbett TH, Valeriote FA, Demchik L, Polin L, Panchapor C, Pugh S, White K, Knight J, Jones J, Jones L, LoRusso P, Foster B, Wiegand RA, Lisow L, Golakoti T, Heltzel CE, Ogino J, Patterson GM, Moore RE. Corbett TH, et al. Among authors: wiegand ra. J Exp Ther Oncol. 1996 Mar;1(2):95-108. J Exp Ther Oncol. 1996. PMID: 9414393

2

Pharmacokinetics and tissue distribution of cryptophycin 52 (C-52) epoxide and cryptophycin 55 (C-55) chlorohydrin in mice with subcutaneous tumors.

Boinpally RR, Polin L, Zhou SL, Jasti BR, Wiegand RA, White K, Kushner J, Horwitz JP, Corbett TH, Parchment RE. Boinpally RR, et al. Among authors: wiegand ra. Cancer Chemother Pharmacol. 2003 Jul;52(1):25-33. doi: 10.1007/s00280-003-0621-0. Epub 2003 May 9. Cancer Chemother Pharmacol. 2003. PMID: 12739061

3

Cryptophycin 1 cellular levels and effects in vitro using L1210 cells.

Foster BJ, Fortuna M, Media J, Wiegand RA, Valeriote FA. Foster BJ, et al. Among authors: wiegand ra. Invest New Drugs. 1998-1999;16(3):199-204. doi: 10.1023/a:1006148127527. Invest New Drugs. 1998. PMID: 10360599

4

Inhibition of macromolecular synthesis by cryptophycin-52.

Subramanian B, Nakeff A, Media JE, Wiegand RA, Valeriote FA. Subramanian B, et al. Among authors: wiegand ra. Anticancer Drugs. 2002 Nov;13(10):1061-8. doi: 10.1097/00001813-200211000-00010. Anticancer Drugs. 2002. PMID: 12439340

5

Pharmacokinetic studies in mice of two new thioxanthenones (183577 and 232759) that showed preferential solid tumor activity.

Foster BJ, Wiegand RA, Pugh S, LoRusso PM, Rake J, Corbett TH. Foster BJ, et al. Among authors: wiegand ra. Clin Cancer Res. 1997 Nov;3(11):2047-53. Clin Cancer Res. 1997. PMID: 9815596

6

Pharmacokinetics of 9-methoxy-N,N-dimethyl-5-nitropyrazolo [3,4, 5-kl]acridine-2(6H)-propanamine (PZA, PD 115934, NSC 366140) in mice: guidelines for early clinical trials1.

Foster BJ, Wiegand RA, LoRusso PM, Baker LH. Foster BJ, et al. Among authors: wiegand ra. Clin Cancer Res. 1995 Aug;1(8):831-7. Clin Cancer Res. 1995. PMID: 9816052

7

Preclinical pharmacokinetic, antitumor and toxicity studies with CI-994 (correction of CL-994) (N-acetyldinaline).

Foster BJ, Jones L, Wiegand R, LoRusso PM, Corbett TH. Foster BJ, et al. Invest New Drugs. 1997;15(3):187-94. doi: 10.1023/a:1005846026398. Invest New Drugs. 1997. PMID: 9387041

8

Identification and antitumor activity of a reduction product in the murine metabolism of pyrazoloacridine (NSC-366140).

Palomino E, Foster B, Kempff M, Corbett T, Wiegand R, Horwitz J, Baker L. Palomino E, et al. Cancer Chemother Pharmacol. 1996;38(5):453-8. doi: 10.1007/s002800050510. Cancer Chemother Pharmacol. 1996. PMID: 8765439

9

A stable isotope-labeled internal standard is essential for correcting for the interindividual variability in the recovery of lapatinib from cancer patient plasma in quantitative LC-MS/MS analysis.

Wu J, Wiegand R, LoRusso P, Li J. Wu J, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Dec 15;941:100-8. doi: 10.1016/j.jchromb.2013.10.011. Epub 2013 Oct 16. J Chromatogr B Analyt Technol Biomed Life Sci. 2013. PMID: 24189203 Free PMC article.

10

A phase I clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a phase I accelerated titration "2B" design.

Gadgeel SM, Boinpally RR, Heilbrun LK, Wozniak A, Jain V, Redman B, Zalupski M, Wiegand R, Parchment R, LoRusso PM. Gadgeel SM, et al. Invest New Drugs. 2003 Feb;21(1):63-74. doi: 10.1023/a:1022972427532. Invest New Drugs. 2003. PMID: 12795531 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

28 results

Search Page

Filters